Notice Regarding Discontinuation of Development of GYM329 (Emugrobart) in Spinal Muscular Atrophy (SMA) and Facioscapulohumeral Muscular Dystrophy (FSHD)
TOKYO, March 23, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche has deci...
Publisher
Japan
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
TOKYO, March 23, 2026 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche has deci...
Source route
Continue on chugai-pharm.co.jp
Leave the platform to read the original full article on the publisher site.
Source: Chugai Pharmaceutical
Scope: Industry
Related coverage
More related coverage
Mar.26.2026R & DOno Pharma Submits an Application for Approval of Ripretinib (DCC-2618) in Patients with Advanced Gastrointestinal Stromal Tumor in Japan
Application submitted for manufacturing and marketing approval of ripretinib in Japan for the indica...
March 25, 2026
Terns’ lead candidate TERN-701 is an investigational oral allosteric BCR::ABL1 tyrosine kinase inhib...
Takeda Transformation Strengthen Competitiveness Future Growth
2026 03 24 06 00 00 3260948
Sanofi and Regeneron’s Dupixent approved in Japan as the first targeted medicine to treat adults wit...